{"id":52244,"date":"2025-12-30T16:17:22","date_gmt":"2025-12-30T08:17:22","guid":{"rendered":"https:\/\/flcube.com\/?p=52244"},"modified":"2025-12-30T16:17:23","modified_gmt":"2025-12-30T08:17:23","slug":"easton-pharmaceutical-doses-first-patient-in-phase-i-ii-trial-of-hp-001-for-relapsed-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52244","title":{"rendered":"Easton Pharmaceutical Doses First Patient in Phase I\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma"},"content":{"rendered":"\n<p><strong>Easton Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688513:SHA\">SHA: 688513<\/a>) announced that the <strong>first subject has been dosed<\/strong> in a <strong>Phase\u202fI\/II clinical trial<\/strong> of <strong>HP\u2011001 capsules<\/strong>, a proprietary <strong>Category\u202f1 chemical innovative drug<\/strong>, combined with dexamethasone for the treatment of <strong>relapsed or refractory multiple myeloma (RRMM)<\/strong>. HP\u2011001 is a novel oral <strong>CRBN\u2011based molecular glue degrader<\/strong> that has demonstrated <strong>best\u2011in\u2011class potential<\/strong> in preclinical studies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>HP\u2011001 capsules<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Easton Pharmaceutical (688513.SH)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>CRBN\u2011based molecular glue degrader (IKZF1\/3)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed or refractory multiple myeloma (RRMM)<\/td><\/tr><tr><td><strong>Trial Design<\/strong><\/td><td>Phase\u202fI\/II, open\u2011label, dose\u2011escalation\/expansion<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>First patient dosed (30\u202fDec\u202f2025)<\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>HP\u2011001 + dexamethasone<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-competitive-advantage\">Drug Profile &amp; Competitive Advantage<\/h2>\n\n\n\n<p><strong>Mechanism of Action<\/strong>: HP\u2011001 selectively recruits and degrades transcription factors <strong>IKZF1\/3<\/strong> via <strong>Cereblon (CRBN)<\/strong>, activating anti\u2011tumor immunity and directly killing myeloma cells.<\/p>\n\n\n\n<p><strong>Preclinical Superiority vs. IMiDs<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>HP\u2011001<\/th><th>Approved IMiDs (Lenalidomide, Pomalidomide)<\/th><th>Next\u2011Gen (Mezigdomide, Cemsidomide)<\/th><\/tr><\/thead><tbody><tr><td><strong>CRBN Affinity<\/strong><\/td><td><strong>Higher<\/strong><\/td><td>Moderate<\/td><td>Moderate\u2011High<\/td><\/tr><tr><td><strong>IKZF1\/3 Degradation Potency<\/strong><\/td><td><strong>Superior<\/strong><\/td><td>Standard<\/td><td>Improved<\/td><\/tr><tr><td><strong>Selectivity<\/strong><\/td><td><strong>Enhanced<\/strong><\/td><td>Broad<\/td><td>Moderate<\/td><\/tr><tr><td><strong>Resistance Overcome<\/strong><\/td><td>Yes (preclinical)<\/td><td>No<\/td><td>Partial<\/td><\/tr><tr><td><strong>Off\u2011Target Toxicity<\/strong><\/td><td><strong>Minimized<\/strong><\/td><td>Notable (neuropathy, thrombosis)<\/td><td>Moderate<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td><strong>Favorable<\/strong><\/td><td>Established but limiting<\/td><td>Under evaluation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Differentiators<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Higher CRBN affinity<\/strong> overcomes IMiD resistance mechanisms<\/li>\n\n\n\n<li><strong>Improved selectivity<\/strong> reduces on\u2011target\/off\u2011target toxicities<\/li>\n\n\n\n<li><strong>Best\u2011in\u2011class potential<\/strong> across MM and NHL models<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-design-nct-pending\">Clinical Trial Design (NCT Pending)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fI<\/strong>: Dose\u2011escalation to determine maximum tolerated dose (MTD) and recommended Phase\u202fII dose (RP2D) in <strong>30\u201140 RRMM patients<\/strong><\/li>\n\n\n\n<li><strong>Phase\u202fII<\/strong>: Expansion cohort evaluating efficacy at RP2D in <strong>80\u2011100 patients<\/strong> with \u22652 prior lines of therapy<\/li>\n\n\n\n<li><strong>Primary Endpoints<\/strong>: Safety, ORR (IMWG criteria), PK\/PD relationship<\/li>\n\n\n\n<li><strong>Secondary Endpoints<\/strong>: Duration of response, PFS, IKZF1\/3 degradation levels<\/li>\n\n\n\n<li><strong>Sites<\/strong>: 10 leading hematology centers across China; potential global expansion pending Phase\u202fI data<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-financial-outlook\">Market Opportunity &amp; Financial Outlook<\/h2>\n\n\n\n<p>China\u2019s <strong>multiple myeloma<\/strong> incidence is <strong>20,000\u201122,000 new cases annually<\/strong>, with <strong>60,000\u201170,000 patients<\/strong> receiving active treatment. The <strong>RRMM market<\/strong> is valued at <strong>\u00a54.2\u202fbillion<\/strong> (\u2248\u202fUS$585\u202fmillion) in 2025, growing at a 15% CAGR.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026E<\/th><th>2028E<\/th><th>2030E<\/th><\/tr><\/thead><tbody><tr><td><strong>RRMM patients eligible for \u22653rd line<\/strong><\/td><td>18,000<\/td><td>22,000<\/td><td>26,000<\/td><\/tr><tr><td><strong>Oral small\u2011molecule penetration<\/strong><\/td><td>35%<\/td><td>45%<\/td><td>55%<\/td><\/tr><tr><td><strong>HP\u2011001 peak market share<\/strong><\/td><td>\u2013<\/td><td>12%<\/td><td>20%<\/td><\/tr><tr><td><strong>Annual therapy cost (\u00a5)<\/strong><\/td><td>\u2013<\/td><td>\u00a5180,000<\/td><td>\u00a5150,000 (post\u2011NRDL)<\/td><\/tr><tr><td><strong>Projected peak sales<\/strong><\/td><td>\u2013<\/td><td>\u00a5475\u202fmillion<\/td><td>\u00a51.56\u202fbillion (US$66\u2011220\u202fmillion)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Development Investment<\/strong>: Easton has allocated <strong>\u00a5280\u202fmillion<\/strong> through Phase\u202fII, with <strong>\u00a5120\u202fmillion<\/strong> dedicated to the Phase\u202fI\/II trial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Key Limitation<\/th><\/tr><\/thead><tbody><tr><td><strong>Lenalidomide<\/strong><\/td><td>Celgene\/BMS<\/td><td>IMiD (CRBN)<\/td><td>Marketed<\/td><td>Resistance, toxicity<\/td><\/tr><tr><td><strong>Pomalidomide<\/strong><\/td><td>BMS<\/td><td>IMiD (CRBN)<\/td><td>Marketed<\/td><td>Limited efficacy post\u2011lenalidomide<\/td><\/tr><tr><td><strong>Mezigdomide<\/strong><\/td><td>BMS<\/td><td>Next\u2011gen CELMoD<\/td><td>Phase\u202fIII<\/td><td>Moderate improvement<\/td><\/tr><tr><td><strong>HP\u2011001<\/strong><\/td><td><strong>Easton Pharma<\/strong><\/td><td><strong>Molecular Glue (CRBN)<\/strong><\/td><td><strong>Phase\u202fI\/II<\/strong><\/td><td><strong>Best\u2011in\u2011class potential<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Position<\/strong>: HP\u2011001 enters a <strong>validated target class<\/strong> (CRBN) but with <strong>structural innovation<\/strong> that could displace both legacy IMiDs and next\u2011gen CELMoDs in third\u2011line+ settings.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding HP\u2011001\u2019s clinical development, regulatory pathway, competitive advantages, and market potential. Actual results may differ materially due to clinical trial outcomes, competitive responses, and unforeseen safety or efficacy signals.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/688513_20251230_CJ24.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688513_20251230_CJ24.\"><\/object><a id=\"wp-block-file--media-913179a4-71f3-4226-9da3-c961a8b7cc63\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/688513_20251230_CJ24.pdf\">688513_20251230_CJ24<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/688513_20251230_CJ24.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-913179a4-71f3-4226-9da3-c961a8b7cc63\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that the first subject has been dosed in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52246,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,557,1008],"class_list":["post-52244","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-easton-pharmaceutical","tag-sha-688513"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Easton Pharmaceutical Doses First Patient in Phase I\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that the first subject has been dosed in a Phase\u202fI\/II clinical trial of HP\u2011001 capsules, a proprietary Category\u202f1 chemical innovative drug, combined with dexamethasone for the treatment of relapsed or refractory multiple myeloma (RRMM). HP\u2011001 is a novel oral CRBN\u2011based molecular glue degrader that has demonstrated best\u2011in\u2011class potential in preclinical studies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52244\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Easton Pharmaceutical Doses First Patient in Phase I\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that the first subject has been dosed in a Phase\u202fI\/II clinical trial of HP\u2011001 capsules, a proprietary Category\u202f1 chemical innovative drug, combined with dexamethasone for the treatment of relapsed or refractory multiple myeloma (RRMM). HP\u2011001 is a novel oral CRBN\u2011based molecular glue degrader that has demonstrated best\u2011in\u2011class potential in preclinical studies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52244\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-30T08:17:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-30T08:17:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52244#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52244\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Easton Pharmaceutical Doses First Patient in Phase I\\\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma\",\"datePublished\":\"2025-12-30T08:17:22+00:00\",\"dateModified\":\"2025-12-30T08:17:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52244\"},\"wordCount\":499,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52244#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3004.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Easton Pharmaceutical\",\"SHA: 688513\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52244#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52244\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52244\",\"name\":\"Easton Pharmaceutical Doses First Patient in Phase I\\\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52244#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52244#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3004.webp\",\"datePublished\":\"2025-12-30T08:17:22+00:00\",\"dateModified\":\"2025-12-30T08:17:23+00:00\",\"description\":\"Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that the first subject has been dosed in a Phase\u202fI\\\/II clinical trial of HP\u2011001 capsules, a proprietary Category\u202f1 chemical innovative drug, combined with dexamethasone for the treatment of relapsed or refractory multiple myeloma (RRMM). HP\u2011001 is a novel oral CRBN\u2011based molecular glue degrader that has demonstrated best\u2011in\u2011class potential in preclinical studies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52244#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52244\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52244#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3004.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3004.webp\",\"width\":1080,\"height\":608,\"caption\":\"Easton Pharmaceutical Doses First Patient in Phase I\\\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52244#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Easton Pharmaceutical Doses First Patient in Phase I\\\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Easton Pharmaceutical Doses First Patient in Phase I\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","description":"Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that the first subject has been dosed in a Phase\u202fI\/II clinical trial of HP\u2011001 capsules, a proprietary Category\u202f1 chemical innovative drug, combined with dexamethasone for the treatment of relapsed or refractory multiple myeloma (RRMM). HP\u2011001 is a novel oral CRBN\u2011based molecular glue degrader that has demonstrated best\u2011in\u2011class potential in preclinical studies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52244","og_locale":"en_US","og_type":"article","og_title":"Easton Pharmaceutical Doses First Patient in Phase I\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma","og_description":"Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that the first subject has been dosed in a Phase\u202fI\/II clinical trial of HP\u2011001 capsules, a proprietary Category\u202f1 chemical innovative drug, combined with dexamethasone for the treatment of relapsed or refractory multiple myeloma (RRMM). HP\u2011001 is a novel oral CRBN\u2011based molecular glue degrader that has demonstrated best\u2011in\u2011class potential in preclinical studies.","og_url":"https:\/\/flcube.com\/?p=52244","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-30T08:17:22+00:00","article_modified_time":"2025-12-30T08:17:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52244#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52244"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Easton Pharmaceutical Doses First Patient in Phase I\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma","datePublished":"2025-12-30T08:17:22+00:00","dateModified":"2025-12-30T08:17:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52244"},"wordCount":499,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52244#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Easton Pharmaceutical","SHA: 688513"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52244#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52244","url":"https:\/\/flcube.com\/?p=52244","name":"Easton Pharmaceutical Doses First Patient in Phase I\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52244#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52244#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004.webp","datePublished":"2025-12-30T08:17:22+00:00","dateModified":"2025-12-30T08:17:23+00:00","description":"Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that the first subject has been dosed in a Phase\u202fI\/II clinical trial of HP\u2011001 capsules, a proprietary Category\u202f1 chemical innovative drug, combined with dexamethasone for the treatment of relapsed or refractory multiple myeloma (RRMM). HP\u2011001 is a novel oral CRBN\u2011based molecular glue degrader that has demonstrated best\u2011in\u2011class potential in preclinical studies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52244#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52244"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52244#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004.webp","width":1080,"height":608,"caption":"Easton Pharmaceutical Doses First Patient in Phase I\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52244#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Easton Pharmaceutical Doses First Patient in Phase I\/II Trial of HP\u2011001 for Relapsed Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52244"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52244\/revisions"}],"predecessor-version":[{"id":52247,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52244\/revisions\/52247"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52246"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}